{"denoms":[{"counts":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"58"}],"units":"Participants"}],"groups":[{"description":"Dose of Cyclophosphamide depended on how many patients we had treated:\n\n* Dose Level 1: Cyclophosphamide 250 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Dose Level 2: Cyclophosphamide 500 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Dose Level 3: Cyclophosphamide 750 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Dose Level 4: Cyclophosphamide 750 mg /m\\^2 IV Day 1; VELCADE, 1.3 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12","id":"BG000","title":"A. Phase I - Dose Escalation"},{"description":"Participants received Cyclophosphamide and VELCADE at the MPD at the same schedule of the Phase I study. Pegylated doxorubicin and Dexamethasone were given at the same doses and schedule as the Phase I part of study.","id":"BG001","title":"B. Phase II - Maximum Planned Dose (MPD)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"42"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"16"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"46","upperLimit":"77","value":"58.75"},{"groupId":"BG001","lowerLimit":"25","upperLimit":"75","value":"57"},{"groupId":"BG002","lowerLimit":"25","upperLimit":"77","value":"57"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"24"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"34"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"58"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Overall Survival by disease risk stratification: 54 participants with cytogenetics and fluorescence in situ hybridisation (FISH) results available for risk stratification. All other measures: 58 Participants."}